Not finding it? Sign in to also search OpenAlex live.
-
Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).2022 Journal of Clinical Oncology conference-abstract Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
Linde Kehmann, Marie Berres, Maria Angeles Gonzalez-Carmona, Dominik Paul Modest, Raphael U. Mohr, Alexander Wree, +6 more
1citations -
Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study
Selim Corbacioglu, Jarl Mooyaart, Emmanuelle Polge, William Boreland, Jessica Lemaitre, Christophe Peczynski, +20 more
2citations -
Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, +14 more
12citations -
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +18 more
0citations -
Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
Hareth Nahi, Saad Z. Usmani, María‐Victoria Mateos, Niels W.C.J. van de Donk, Philippe Moreau, Albert Oriol, +8 more
2citations -
Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.2020 Journal of Clinical Oncology conference-abstract Medicine Multiple Myeloma Research and Treatments Open access cited by 5 patents
Hareth Nahi, María‐Victoria Mateos, Niels W.C.J. van de Donk, Philippe Moreau, Albert Oriol, Torben Plesner, +7 more
2citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Abstract CT194: Low-dose Interferon-alpha pre-conditioning and adoptive cell therapy in metastatic melanoma patients refractory to standard (immune) therapies - a phase 1/2 study
Monique K. van der Kooij, Els M.E. Verdegaal, Marten Visser, Carolien E. van der Minne, Linda de Bruin, Pauline Meij, +8 more
0citations -
Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial
Joost S.P. Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Yoon Cheah, Justin M. Darrah, +7 more
6citations -
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
Joost S.P. Vermaat, Pim G. N. J. Mutsaers, Sébastien Anguille, Maria Theresa Kuipers, Évelyne Willems, Tim J. A. Dekker, +13 more
2citations -
Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
Susanne Isfort, Dominik Georg Friedrich Wolf, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +11 more
5citations -
Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
Julia Marie Unglaub, Richard F. Schlenk, Maher Hanoun, Hans Christian Reinhardt, Jan Moritz Middeke, Kerstin Schäfer‐Eckart, +30 more
4citations -
Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT
Carmelo Gurnari, Linda Köster, Laurien G.A. Baaij, Maël Heiblig, Ibrahim Yakoub‐Agha, Jakob Robert Passweg, +18 more
5citations -
Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial
Natalia Tovar, Valentín Ortiz‐Maldonado, Núria Martínez‐Cibrián, Sergi Betriu, Daniel Esteban, Ana Triguero, +5 more
5citations -
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.2023 Journal of Clinical Oncology conference-abstract Medicine Multiple Myeloma Research and Treatments Open access
Bhagirathbhai Dholaria, Katja Christina Weisel, María‐Victoria Mateos, Hartmut Goldschmidt, Thomas G. Martin, Daniel Morillo, +14 more
66citations